drugset / Trial / NCT02675023

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

NCT02675023

Phase 1 Completed 603 enrolled Momenta Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelOther

Summary

This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.

Timeline

Start
2016-01
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject M923 Monoclonal antibody 40 mg Subcutaneous

Indications

No indication recorded.